Help
MLCi s an international medical technology (MedTech) project engaged in the development and implementation of modern health diagnostic systems.
This humanitarian initiative has a global goal: to improve the quality of life and longevity for millions of people through technological solutions.
The project covers all stages: from research and development and technology patenting to contract manufacturing, distribution, and investment attraction.
MLC's mission :
To create accessible and high-performance technologies for health diagnostics and monitoring, helping people live longer and better lives..
MLC's goals :
Introducing innovative developments to the global market.
Building solid reputation and global presence for the MLC brand.
The project operates in the MedTech (medical technology) sector, one of the fastest-growing industries in the world.
According to a market research study commissioned by MLC and conducted by MegaResearch, the market is expected to grow annually by 15% to 30%.
By 2045, the CGM market will increase 21-fold to reach $ 233 billion.
MedTech encompasses monitoring, diagnostic, preventative, and health management technologies, and MLC occupies a niche in this sector, providing glucose monitoring devices (CGM) and other solutions for the mass market.
MLC's product selection is based on a strategic analysis of trends, needs, and technological capabilities:
Our specialists research what technologies will be in demand in the coming years.
We select areas where we can develop our own solution and enter the market with a competitive product.
The key criteria are high demand, scalability, patent protection, and rapid monetization.
MLC.Health is a digital platform where anyone can:
- Register as an investor or project partner.
- Purchase investment shares and participate in profit sharing.
- Sign documents online with full electronic document management.
- Get access to marketing materials, partner program tools, and analytics.
Our technical operator, Commerce CloudSoft LTD (CCS, UK), ensures the full functionality of the personal office platform, its stability, and secure electronic document management.
The main source of income after establishing production is worldwide sales through a network of distributors.
Several memorandums of intent have already been signed with Middle Eastern countries to cooperate in the sales of finished products.
Most of the wholesale distribution activities are handled by MLC Technologies Limited in Hong Kong.
To ensure legal guarantees, high transparency, and enhanced legal protection, the project has a unique international legal structure.
MLC GT LLC-FZ (UAE) is the management company, intellectual property holder, and technology developer.
Company's address: Meydan Grandstand, 6th floor, Meydan Road,
Nad Al Sheba, Dubai, UAE.
UICOM – FZCO (UAE) is a licensed investment company providing international legal and financial support.
Schengen MLC Technologies L.L.C (China, Shenzhen) is the product manufacturer.
MLC Technologies Limited (Hong Kong) is the wholesale distributor.
You can find all legal documents in the Documents section, Project Documents tab.
https://my.mlc.health/en/document/project-docs
MLC GT manages the project, develops investment proposals, and oversees the implementation of goals. Relationships:
Receiving investment from UICOM-FZCO.
Transfering research results and intellectual property from InnoBioSystems to the production.
Partnering with Commerce CloudSoft to manage the platform and partner programs.
Commerce CloudSoft is responsible for the project's IT infrastructure, MLC.Health platform management, and partner program implementation. Interaction with UICOM:
The platform is used to manage investor and partner data transferred through UICOM.
It ensures the transparency and accuracy of financial transactions.
UICOM-FZCO acts as a financial intermediary, attracting investments and transfering them to MLC GT. Interaction:
Collaborating with Commerce CloudSoft to manage investor data.
Forwarding funds to MLC GT to fund projects.
UICOM transfers investor and partner data to Commerce CloudSoft for further analysis, platform management, and partner program implementation. Commerce CloudSoft provides IT support and transaction monitoring.
UICOM transfers investment funds to MLC GT, thus providing project funding. MLC GT uses the proceeds to develop and implement projects.
MLC GT enters into agreements with InnoBioSystems for research and intellectual property development. R&D results are transferred to MLC GT for subsequent implementation into production
The production management company is a subsidiary, MLC Technologies Limited, registered in the jurisdiction of Hong Kong.
MLC Technologies Limited (Hong Kong) is the founder of a manufacturing company in China, Shenzhen MLC Technologies LLC. This company operates as a WFOE (Wholly Foreign-Owned Enterprise), a commercial enterprise in China wholly owned by foreign investors.
Shenzhen MLC Technologies LLC enters into direct contracts for manufacturing products under the CDMO (Contract Development and Manufacturing Organization) principle, and also purchases components for the CDMO and acts as the customer for product certification.
Products manufactured by Shenzhen MLC Technologies LLC are sold through supply contracts entered into by customers and MLC Technologies Limited (Hong Kong).
The profit earned by MLC Technologies Limited (Hong Kong), generated from the difference between costs and gains, constitutes the revenue.
MLC Technologies Limited (Hong Kong) transfers the company's generated profits to its founder, MLC GT L.L.C-FZ. Having obligations under investment agreements, MLC GT L.L.C-FZ distributes profits among the production investors.